Associated Papers
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG et al.
Aids (london, England), 2002
Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
Gatanaga H et al.
The Journal of Biological Chemistry, 2002
DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
Kaltenbach RF et al.
Antimicrobial Agents and Chemotherapy, 2001
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.
Croteau G et al.
Journal of Virology, 1997
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
Doyon L et al.
Journal of Virology, 1996
Select a paper to view details